A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
for Plaque Psoriasis
Drug: Deucravacitinib
42 locations incl. Birmingham
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 12 - 17
Code: NCT06979453·Phase 3·Recruiting